Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.54 |
| ▸ | F9 | P00740 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4203009 | 0.99 | F2 (0.54) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL3924327 | 0.93 | CYP3A4 (0.62) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4207332 | 0.91 | CYP3A4 (0.57) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4199829 | 0.88 | CYP3A4 (0.54) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4204855 | 0.88 | CYP3A4 (0.54) | F2PRSS1F11KLKB1F9 | |
| Hydrochloric Acid SCHEMBL4201962 | 0.87 | CYP3A4 (0.53) | F2PRSS1F11KLKB1F9 | |
| Hydrochloric Acid SCHEMBL4202871 | 0.87 | CYP3A4 (0.53) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4208081 | 0.86 | CYP3A4 (0.53) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4207051 | 0.85 | CYP3A4 (0.56) | F2PRSS1F11KLKB1F9 | |
| SCHEMBL4199134 | 0.85 | CYP3A4 (0.56) | F2PRSS1F11KLKB1F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | TFPI, TFPI2, ADAMTS1 | F2 23/4885PRSS1 17/4885F11 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.